Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly

- Stephen Fry to retire at the end of 2022

- Eric Dozier named Senior Vice President, Human Resources and Diversity

- Winselow Tucker to join Lilly as Senior Vice President and Chief Commercial Officer for Loxo@Lilly

INDIANAPOLIS, Aug. 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hiring of a new chief commercial officer for Loxo@Lilly.

After more than 35 years at Lilly, Stephen Fry, senior vice president, human resources and diversity, will retire at the end of 2022.

Commenting on Fry's retirement, David A. Ricks, Lilly chair and CEO, said, "Steve has left a positive and indelible imprint on the people, culture and performance of our company. Serving as our CHRO over the past 11 years, Steve has played a key role in leading us through the challenges we faced in those early years, modernizing so many dimensions of our HR function—including diversity, equity and inclusion—and leading the company's efforts to become a premier employer around the world. His depth of knowledge about our business, commitment to Lilly, and expertise in human resources will be missed by employees, management, and our board.  We wish Steve all the best in his well-earned transition to retirement."

Eric Dozier, currently vice president and chief commercial officer for Loxo@Lilly, is being promoted to succeed Fry as senior vice president, human resources and diversity. Dozier will report to Ricks and join Lilly's Executive Committee upon Fry's retirement.

"Eric is the right leader to drive our people strategy and diversity, equity, and inclusion agenda as Lilly enters a new and exciting chapter of growth," said Ricks. "A long-tenured Lilly executive who understands our strong heritage and culture, Eric has led transformative change across the enterprise, has a track record of developing people and teams that deliver strong business results, and has the trust of his Lilly colleagues."

During his nearly 25-year career with Lilly, Dozier has held roles of expanding responsibility in the company's commercial business across multiple therapeutic areas, including serving as chief marketing officer for the Japan affiliate. Prior to his current role, Dozier served as vice president of global ethics and compliance.

Succeeding Dozier will be Winselow Tucker, who joins Lilly at the end of August as senior vice president and chief commercial officer for Loxo@Lilly, reporting to Jacob Van Naarden, senior vice president and CEO of Loxo@Lilly.  Winselow joins Lilly from Bristol Myers Squibb, where he served as senior vice president and general manager of US Hematology before assuming his current responsibilities as senior vice president, intercontinental, earlier this year. Prior to joining BMS, Winselow held leadership roles at Novartis and Celgene. He holds a bachelor's degree in business administration from Howard University and a Master of Business Administration from Indiana University.

"Winselow brings deep expertise in both oncology and hematology that will support the continued growth of our existing commercial portfolio and efforts to bring our pipeline of cancer medicines to patients around the world," said Van Naarden.

About Lilly

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom. C-LLY

Lilly Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including related to leadership changes and Lilly's strategy, and reflects Lilly's current beliefs and expectations. There can be no assurance that the leadership changes will achieve Lilly's objectives or that Lilly will execute its strategy as planned. For further discussion of risks and uncertainties relevant to Lilly's business, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements. 

SOURCE Eli Lilly and Company